Arrowhead Regional Medical Center Converts to Masimo rainbow Technology for Advanced Noninvasive Patient Monitoring Capabilities

IRVINE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Arrowhead Regional Medical Center (ARMC) in Colton, California, and Masimo (Nasdaq: MASI), the inventor of Masimo rainbow Pulse CO-Oximetry™, Masimo rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the completion of ARMC's system-wide conversion to Masimo rainbow technology.  The conversion ensures that all ARMC patients can be monitored using the most technologically and clinically-advanced noninvasive patient monitoring technologies available—providing real-time measurement results for critical physiological parameters that help clinicians to more rapidly assess, diagnose, and treat patients.  

"The decision to convert our network to the Masimo rainbow technology platform came down to wanting to equip our facility with the best and most advanced noninvasive patient monitoring capabilities available," stated Patrick Petre, Director at Arrowhead Regional Medical Center. "Our mission is to provide quality care to the community using the most advanced patient care technology."

The system-wide conversion standardizes all of ARMC's sites of care to Masimo rainbow technology—the only upgradeable pulse oximetry platform that allows hospitals to add breakthrough noninvasive blood constituent, hemodynamic, and respiration measurement capabilities that previously required invasive procedures.  The ability to continuously and noninvasively measure total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to Masimo SET 'gold standard' Measure-Through Motion and Low Perfusion oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR) measurements enables monitoring of multiple physiological parameters simultaneously—facilitating earlier detection and treatment of life-threatening conditions.  The conversion involved upgrading virtually all of the hospital's multiparameter patient monitors, oximeters, and sensors to enable the new patient monitoring capabilities.  

"This upgrade is important because it enables us to now provide noninvasive, technologically-advanced monitoring technologies to our patients," said Dr. David T. Wong, a surgeon and chief of Trauma and Critical Care Services at ARMC. "It also provides flexibility in that we can now continuously monitor blood constituents, fluid responsiveness, and advanced oxygen delivery parameters, in addition to the more common measurements of arterial saturation and pulse rate."

Masimo Founder and CEO, Joe Kiani, stated, "Arrowhead Regional Medical Center joins a growing list of the world's most demanding hospitals standardizing to Masimo rainbow as their universal oximetry solution.  Offering the most advanced noninvasive measurement capabilities, our rainbow oximetry platform helps state-of-the-art hospitals leverage cutting-edge medical technologies that improve patient outcomes and reduce the cost of care."

About Arrowhead Regional Medical Center

Arrowhead Regional Medical Center is a state-of-the-art 456-bed acute care facility featuring the newest technology in the field of patient care. The Medical Center is the host to a 24-hour Emergency Department, Level II Trauma Center, three Family Health Centers and the only Burn Center serving San Bernardino, Riverside, Inyo and Mono counties.  For more information, visit:  www.arrowheadmedcenter.org

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET and Masimo rainbow oximetry technologies will provide sufficient sensitivity and specificity to accurately detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, risks related to our belief that Masimo SET and rainbow measurements will help clinicians guide treatment options, risks related to our assumptions regarding the repeatability of clinical results, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED